Liquidia/$LQDA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Liquidia
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
Ticker
$LQDA
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
170
ISIN
US53635D2027
Website
Liquidia Metrics
BasicAdvanced
$1.2B
-
-$1.71
0.04
-
Price and volume
Market cap
$1.2B
Beta
0.04
52-week high
$19.41
52-week low
$8.26
Average daily volume
2.6M
Financial strength
Current ratio
2.928
Quick ratio
2.826
Long term debt to equity
220.592
Total debt to equity
297.035
Interest coverage (TTM)
-9.14%
Profitability
EBITDA (TTM)
-126.359
Gross margin (TTM)
58.08%
Net profit margin (TTM)
-980.47%
Operating margin (TTM)
-904.40%
Revenue per employee (TTM)
$80,000
Management effectiveness
Return on assets (TTM)
-37.66%
Return on equity (TTM)
-203.98%
Valuation
Price to revenue (TTM)
81.187
Price to book
24.28
Price to tangible book (TTM)
28.27
Price to free cash flow (TTM)
-10.693
Free cash flow yield (TTM)
-9.35%
Free cash flow per share (TTM)
-132.33%
Growth
Revenue change (TTM)
-11.42%
Earnings per share change (TTM)
19.43%
3-year revenue growth (CAGR)
2.17%
3-year earnings per share growth (CAGR)
28.80%
What the Analysts think about Liquidia
Analyst ratings (Buy, Hold, Sell) for Liquidia stock.
Bulls say / Bears say
Liquidia received FDA approval for YUTREPIA™ (treprostinil) inhalation powder on May 23, 2025, enabling the company to enter the market for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) treatments. (liquidia.com)
The company secured an additional $50 million in funding from Healthcare Royalty (HCRx) following the first commercial sale of YUTREPIA™, strengthening its financial position to support product launch and development. (liquidia.com)
A U.S. District Court denied United Therapeutics' request for a preliminary injunction against Liquidia, allowing the company to proceed with the commercial launch of YUTREPIA™ without legal hindrance. (liquidia.com)
Liquidia is under investigation for potential violations of securities laws, which could lead to legal challenges and financial penalties. (stockhouse.com)
The company faces ongoing litigation from United Therapeutics, including a new lawsuit filed in May 2025 alleging patent infringement, which could result in costly legal battles and potential restrictions on YUTREPIA™ sales. (liquidia.com)
Despite recent funding, Liquidia's financial stability may be at risk if YUTREPIA™ sales do not meet expectations, potentially leading to challenges in sustaining operations and funding future developments. (liquidia.com)
Data summarised monthly by Lightyear AI. Last updated on 10 Jul 2025.
Liquidia Financial Performance
Revenues and expenses
Liquidia Earnings Performance
Company profitability
Liquidia News
AllArticlesVideos
Liquidia Receives $50 Million from Healthcare Royalty (HCRx) Following First Commercial Sale of YUTREPIA™
GlobeNewsWire·3 weeks ago
Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD
GlobeNewsWire·1 month ago
These Analysts Boost Their Forecasts On Liquidia
Benzinga·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Liquidia stock?
Liquidia (LQDA) has a market cap of $1.2B as of July 11, 2025.
What is the P/E ratio for Liquidia stock?
The price to earnings (P/E) ratio for Liquidia (LQDA) stock is 0 as of July 11, 2025.
Does Liquidia stock pay dividends?
No, Liquidia (LQDA) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next Liquidia dividend payment date?
Liquidia (LQDA) stock does not pay dividends to its shareholders.
What is the beta indicator for Liquidia?
Liquidia (LQDA) has a beta rating of 0.04. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.